Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for health advice, go to the NHS website. And if you are looking for the latest travel information, and advice about the government response to the outbreak, go to the GOV.UK website.
NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C.
Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.
The hepatitis C virus causes inflammation of the liver, affecting its ability to function. Whilst many sufferers naturally clear their infections within six months, others develop chronic hepatitis which is usually life-long without therapy.
Current estimates indicate that around 30% of people infected with chronic hepatitis C will develop cirrhosis of the liver which, in some cases, may prove fatal without a liver transplant.
The recommendation of NHS England’s Clinical Priorities Advisory Group (CPAG) means that whilst not yet NICE-approved, Sofosbuvir will be funded for those patients at significant risk of mortality or who require transplantation.
View NHS England’s policy statement on the funding of Sofosbuvir. The drug, which will be available as an oral formulation, will be used in combination with another antiviral agent.
James Palmer, Clinical Director, Specialised Services, said:
“This is a major step forward for patients with this debilitating, and often life-threatening, disease and is evidence of NHS England’s commitment to widen access to cutting edge drugs, treatments and therapies where both clinically appropriate and cost effective.
“The majority of these patients will already be under the care of a specialist treatment centre, and we will ensure that clinicians are aware of this policy, so that all eligible patients have the opportunity to access this drug”.
Professor Graham Foster, Professor of Hepatology and co-Chair of the Hepatitis C Clinical Reference Group sub-group welcomed the news. He said:
“The recently licensed, new, direct-ac ting antiviral drugs for hepatitis C may be life-saving for infected patients with advanced cirrhosis. I am delighted that NHS England will make these drugs available for these patients and allow us to treat those in urgent need.
“The availability of these drugs will ensure that NHS patients are among the first in Europe to benefit from these revolutionary new drugs”.
NICE is currently developing Technology Appraisal Guidance relating to Sofosbuvir, which is due to be published later this year. The NHS England policy position will be reviewed once NICE has published this guidance.